ASCO 2023 | Primary analysis of TRANSCEND-CLL-004: liso-cel in R/R CLL
William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the primary analysis of the TRANSCEND-CLL-004 study (NCT03331198) which assessed lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) who are refractory to BTK and BCL2 inhibitors. The study met its primary endpoint, with a complete response (CR) rate of 18.4%, and also reported deep and durable responses.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miragen Therapeutics Inc, Novartis, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, Xencor; Nonrelevant Financial Relationship: National Comprehensive Cancer Network (Chair, CLL).
